tbuckley/cabot-search huggingface dataset:
Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry
Authors: Magdalena Kraft, Macarena Pia Knop, Jean‐Marie Renaudin, Kathrin Scherer Hofmeier, Claudia Pföhler, Maria Beatrice Bilò, Roland Lang, Regina Treudler, Nicola Wagner, Thomas Spindler, Jonathan O'B Hourihane, Ioana Maris, Alice Koehli, Andrea Bauer, Lars Lange, Sabine Müller, Nikolaos G. Papadopoulos, Bettina Wedi, Anne Moeser, Luis F. Ensina, Montserrat Fernandez‐Rivas, Ewa Cichocka‐Jarosz, George Christoff, Blanca E. Garcia, Iwona Poziomkowska‐Gęsicka, Victoria Cardona, Tihomir B. Mustakov, Uta Rabe, Vera Mahler, Linus Grabenhenrich, Sabine Dölle‐Bierke, Margitta Worm
Journal: Allergy (2019)

Patients with a history of anaphylaxis are at risk of future anaphylactic reactions. Thus, secondary prevention measures are recommended for these patients to prevent or attenuate the next reaction.Data from the Anaphylaxis Registry were analyzed to identify secondary prevention measures offered to patients who experienced anaphylaxis. Our analysis included 7788 cases from 10 European countries and Brazil.The secondary prevention measures offered varied across the elicitors. A remarkable discrepancy was observed between prevention measures offered in specialized allergy centers (84% of patients were prescribed adrenaline autoinjectors following EAACI guidelines) and outside the centers: Here, EAACI guideline adherence was only 37%. In the multivariate analysis, the elicitor of the reaction, age of the patient, mastocytosis as comorbidity, severity of the reaction, and reimbursement/availability of the autoinjector influence physician's decision to prescribe one.Based on the low implementation of guidelines concerning secondary prevention measures outside of specialized allergy centers, our findings highlight the importance of these specialized centers and the requirement of better education for primary healthcare and emergency physicians.
Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy
Authors: J.H. Park, S.F. Jonas, M.V. Dieci, G. Bataillon, C. Criscitiello, G. Viale, R.F. Salgado, H.J. Lee, S. Loi, S.-B. Kim, G. Curigliano, A. Vincent-Salomon, F. André, S. Michiels
Journal: Annals of Oncology (2019)
Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV-negative oropharyngeal cancer
Authors: K. Prabhash, V.M. Patil, V. Noronha, A.P. Joshi, A. Bhattacharjee, V. Mathrudev, A. Bhelekar, K. Nawale, J.P. Agarwal, S. Ghosh-Laskar, A. Budrukkar, A. Mahajan, A. Agarwal, N. Purandare, P. Chaturvedi, P. Pai, D. Chaukar
Journal: Annals of Oncology (2019)
Active immunization with immune checkpoint inhibitors-mimotope elicits strong anti-tumour effect against HER-2/neu-expressing tumours
Authors: J. Tobias, C. Battin, ASousa De Linhares, M. Lebens, K. Baier, K. Ambroz, S. Högler, A. Inic-Kanada, E. Garner-Spitzer, M. Preusser, L. Kenner, M. Kundi, C.C. Zielinski, P. Steinberger, U. Wiedermann
Journal: Annals of Oncology (2019)
Clinical impact of molecular profiling of cervical cancer (CC) patients (pts) in a dedicated phase I (P1) unit
Authors: M. Scaranti, R. Caldwell, M Selvi Miralles, R. Shinde, A. Pal, J.E. Ang, A. Biondo, C. Guo, E. Cojocaru, S. Gennatas, F. Lockie, C. Bertan, C. Baker, S. Carreira, S. Banerjee, S. Kaye, J.S. de Bono, U. Banerji, A. Minchom, J. Lopez
Journal: Annals of Oncology (2019)
Analytical performance of the resolution-HRD plasma assay used to identify mCRPC patients with biallelic disruption of DNA repair genes for treatment with niraparib
Authors: I. Pekker, L. Lim, J.S. Simon, M. Gormley, Z. Li, J. Pollak, K. Potts, S. Watford, J. Posey, P. Chan, K. Urtishak, K. Garg, A. Hosseini, M. Li
Journal: Annals of Oncology (2019)
A critical appraisal of quality indicators of breast cancer treatment in Belgium
Authors: D M E C Verhoeven, F.P. Duhoux, E. de Azambuja, L. van Walle, K. Punie, H. Wildiers, P. Vuylsteke, A. Barbeaux, N. Van Damme, L. Van Eycken
Journal: Annals of Oncology (2019)
Safety profile of autologous macrophage therapy for liver cirrhosis
Authors: Francesca Moroni, Benjamin J. Dwyer, Catriona Graham, Chloe Pass, Laura Bailey, Lisa Ritchie, Donna Mitchell, Alison Glover, Audrey Laurie, Stuart Doig, Emily Hargreaves, Alasdair R. Fraser, Marc L. Turner, John D. M. Campbell, Neil W. A. McGowan, Jacqueline Barry, Joanna K. Moore, Peter C. Hayes, Diana J. Leeming, Mette J. Nielsen, Kishwar Musa, Jonathan A. Fallowfield, Stuart J. Forbes
Journal: Nature Medicine (2019)
The Two SH2 Domains of SHP-2 Bridge Two PD-1 Molecules Resulting in SHP-2 Activation and PD-1-Mediated Inhibition
Authors: Nikolaos Patsoukis, Jonathan Duke-Cohan, Apoorvi Chaudhri, Eunyoung Park, Council Asia, Anders Berg, Gordon J Freeman, Michael Eck, Vassiliki A Boussiotis
Journal: Blood (2018)
Abstract 16358: Anticoagulation for the Treatment of Cancer-Associated Thrombosis: A Network Meta-Analysis of Randomized Trials
Authors: Diana M Sobieraj, William L Baker, Eni Smith, Katarzyna Sasiela, Stephanie E Trexler, Oliver Kim, Craig I Coleman
Journal: Circulation (2018)

Introduction: Management of cancer associated thrombosis (CAT) with anticoagulation is recommended by guidelines, but its use is complicated by a delicate balance between patients’ increased venous...
An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations
Authors: Umber Dube, Jorge L Del-Aguila, Zeran Li, John P Budde, Shan Jiang, Simon Hsu, Laura Ibanez, Maria Victoria Fernandez, Fabiana Farias, Joanne Norton, Jen Gentsch, Fengxian Wang, Ricardo Allegri, Fatima Amtashar, Tammie Benzinger, Sarah Berman, Courtney Bodge, Susan Brandon, William Brooks, Jill Buck, Virginia Buckles, Sochenda Chea, Patricio Chrem, Helena Chui, Jake Cinco, Jack Clifford, Mirelle D’Mello, Tamara Donahue, Jane Douglas, Noelia Edigo, Nilufer Erekin-Taner, Anne Fagan, Marty Farlow, Angela Farrar, Howard Feldman, Gigi Flynn, Nick Fox, Erin Franklin, Hisako Fujii, Cortaiga Gant, Samantha Gardener, Bernardino Ghetti, Alison Goate, Jill Goldman, Brian Gordon, Julia Gray, Jenny Gurney, Jason Hassenstab, Mie Hirohara, David Holtzman, Russ Hornbeck, Siri Houeland DiBari, Takeshi Ikeuchi, Snezana Ikonomovic, Gina Jerome, Mathias Jucker, Kensaku Kasuga, Takeshi Kawarabayashi, William Klunk, Robert Koeppe, Elke Kuder-Buletta, Christoph Laske, Johannes Levin, Daniel Marcus, Ralph Martins, Neal Scott Mason, Denise Maue-Dreyfus, Eric McDade, Lucy Montoya, Hiroshi Mori, Akem Nagamatsu, Katie Neimeyer, James Noble, Joanne Norton, Richard Perrin, Marc Raichle, John Ringman, Jee Hoon Roh, Peter Schofield, Hiroyuki Shimada, Tomoyo Shiroto, Mikio Shoji, Wendy Sigurdson, Hamid Sohrabi, Paige Sparks, Kazushi Suzuki, Laura Swisher, Kevin Taddei, Jen Wang, Peter Wang, Mike Weiner, Mary Wolfsberger, Chengjie Xiong, Xiong Xu, Stephen Salloway, Colin L Masters, Jae-Hong Lee, Neill R Graff-Radford, Jasmeer P Chhatwal, Randall J Bateman, John C Morris, Celeste M Karch, Oscar Harari, Carlos Cruchaga
Journal: Nature Neuroscience (2019)
Opportunist and serious infections in patients with neuroendocrine tumours treated with everolimus: A multicenter study of real world patients
Authors: C.D.C. Mauro, V.H.F. de Jesus, M. Barros, F.P. Costa, R.F. Weschenfelder, N. D’Agustini, M. Angel, R. Luca, J.E. Nuñez, J.M. O’Connor, R.P. Riechelmann
Journal: Annals of Oncology (2019)
Economic evidence for the prevention and treatment of atopic eczema
Authors: T.H. Sach, E. McManus, N.J. Levell
Journal: British Journal of Dermatology (2019)

Atopic eczema, often called eczema, causes red and itchy skin and can affect people's quality of life. In the UK, one in five children has eczema. As eczema is so common, it might cost a lot for the NHS and the families of affected people. Globally, health care systems don't have enough resources (e.g. money or staff) to provide treatment for all health problems. Because of this, we need economic evidence to help decide how we should use resources, to get the best possible benefits for people for the money we spend on healthcare. This study aims to teach dermatologists about the different economic methods used in medical research, using eczema as an example. A systematic review (a high quality way of reviewing published studies) identified and looked at the quality of previously published economic evidence studies on eczema. Using these studies, the different methods, along with when they should be used, were described. The review found that the number of economic studies available was small compared to the number of clinical studies published each year, with a limited number of and range of different interventions or ways to treat eczema. The most commonly studied treatment was calcineurin inhibitor ointments, followed by infant formula (intended to prevent eczema from developing). To be able to advise on how best to allocate resources, economic evidence needs to look at both the costs and outcomes (results) of two or more treatments. Less than half of the studies found in the review did this. Most studies looked at either costs or outcomes but not both, and so only gave partial evidence. Therefore, more economic research is needed.
Exploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR)
Authors: A. Grothey, S. Hoefman, M. Ruppert, P. Vis, J. Zisowsky, S. Fiala-Buskies, E. Van Cutsem, E. Dochy, A. Cleton, B.A. Ploeger
Journal: Annals of Oncology (2019)
Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab
Authors: Richard S. Hotchkiss, Elizabeth Colston, Sachin Yende, Elliott D. Crouser, Greg S. Martin, Timothy Albertson, Raquel R. Bartz, Scott C. Brakenridge, Matthew J. Delano, Pauline K. Park, Michael W. Donnino, Mark Tidswell, Florian B. Mayr, Derek C. Angus, Craig M. Coopersmith, Lyle L. Moldawer, Ian M. Catlett, Ihab G. Girgis, June Ye, Dennis M. Grasela
Journal: Intensive Care Medicine (2019)
Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4)
Authors: Frits van Rhee, Alan Mitchell, Christoph Heuck, Monica Grazziutti, Yogesh Jethava, Rashid Z Khan, Donald Johann, Bart Barlogie
Journal: Blood (2014)
Abstract 15834: Statins Mediate Recovery From Chemotheraphy-Induced Cardiotoxicity
Authors: Keith Dadson, Paaladinesh Thavendiranathan, Daniela Grothe, Ludger Hauck, Mohammed A Azam, Daoyuan Si, Kumaraswamy Nanthakumar, Fillio Billia
Journal: Circulation (2018)

Introduction: Doxorubicin (Dox) is a frequently used chemotherapeutic agent with heart failure as a major adverse event. Despite decades of study, no translatable therapies have emerged to reverse ...
PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation
Authors: Nicola Tumino, Francesca Besi, Anna Laura Di Pace, Francesca Romana Mariotti, Pietro Merli, Giuseppina Li Pira, Federica Galaverna, Angela Pitisci, Tiziano Ingegnere, Andrea Pelosi, Linda Quatrini, Enrico Munari, Franco Locatelli, Lorenzo Moretta, Paola Vacca
Journal: Leukemia (2019)
Frequency of familiar cancer in a cohort of newly-diagnosed patients with colorectal cancer
Authors: R. Lastra, A. Yubero, M. Ortega, J. Lambea, A. Elena, E. Millastre, M. Ruiz, P. Escudero, A. Saenz, J. I. Mayordomo, A. Tres
Journal: Journal of Clinical Oncology (2006)

13588 Background: Incidence on Hereditary Non Poliposis Colorectal Cancer (HNPCC) is 3–5% of all colorectal cancers (CRC). Primary identification of patients (p) with high risk of this hereditary syndrome is the first step before genetic testing for MSH2, MLH1 or MSH6 mutations. AIMS: To determine the frequency of family history of CRC in our population Methods: We have assessed cancer history (full family pedigree, including at least 2 generations of ascendants plus all descendants) in a cohort of 100 newly-diagnosed p with CRC cancer seen as first visit at the Division of Medical Oncology of the University Hospital of Zaragoza, Spain, from 2005. We have used the revised Bethesda Guideline for HNPCC published in JNCI (Vol 96. Feb 2004) Results: Median age was 72 (range: 26 - 85). 29 females/71 males. Considering Bethesda criteria for genetic testing, percentages of families fulfilling them were: Cancer before age 50: 7 (7%), synchronous/metachronous cancer: 1 (1%), other HNPCC associated tumors before age 50: 1 (ovarian 1%), One first-degree relative with HPNCC related tumor before age 50: 4 (4%), Two or more family members with HNPCC related cancer: 5 (5%). Overall, 14 (14%) fulfilled at least 1 of these criteria. Number of cases of tumors in the family (for a total of 909 family members) was 82, 10 cases of breast cancer, 23 of colorectal, 6 of gastric, 5 of prostate, 3 gynecologic, 11 lung, and 21 others. Conclusions: Frequency of familiar CC in unselected breast cancer patients of Zaragoza, Spain, is substantially higher than that expected. Assessment of cancer familiar history in the newly-diagnosed patients with CC cancer, helps us to identify families in which a genetic study is to be considered, and this could be useful to prevent new case of cancer. No significant financial relationships to disclose.
STUDY OF CELIAC DISEASE SEROLOGY IN PATIENTS WITH JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: AM Shamseya, KA Abdelaty, EH Elsayed, HM Donia, MM Shamseya, AI Ellakany
Journal: Endoscopy (2019)

100 patients with juvenile systemic lupus erythematosus were subjected to detailed history taking, Clinical examination with thorough joint examination Clinical assessment of lupus activity using SLEDAI score Serum levels of anti-tTG Ab IgA & IgG, esophagogastroduodenoscopy (EGD) for those with positive serology for Celiac disease.
GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study
Authors: Daniel J. DeAngelo, Brian A Jonas, Jane L. Liesveld, Dale L. Bixby, Anjali S. Advani, Paula Marlton, Michael O'Dwyer, John L Magnani, Helen M. Thackray, Pamela S. Becker
Journal: Blood (2017)
Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients
Authors: S.L. Groenland, D.R. Geel, J.M. Janssen, J.H. Beijnen, S.A. Burgers, E.F. Smit, A.D.R. Huitema, N. Steeghs
Journal: Annals of Oncology (2019)
PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastatic hormone-sensitive prostate cancer
Authors: J A Arranz Arija, B.P. Valderrama, T Alonso Gordoa, E Gallardo Diaz, J M Sepulveda Sanchez, E. Fernandez-Parra, J.M. Piulats, M J Mendez Vidal, N Sala González, S Vazquez Estevez, N. Lainez, F. Zambrana, M Lázaro Quintela, M A Climent Duran, I. García-Carbonero, C Caballero Diaz, J. Puente, J García Sánchez, J.A. Virizuela, J. Carles
Journal: Annals of Oncology (2019)
MONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+, HER2- advanced breast cancer (ABC)
Authors: M. Martín, S. Johnston, J. Huober, A. Di Leo, J. Sohn, V.A. Andre, H.R. Martin, M.C. Hardebeck, M.P. Goetz
Journal: Annals of Oncology (2019)
HLA-ligandome analysis reveals target antigens of oropharyngeal squamous cell carcinoma
Authors: S. Laban, J. Eziç, L. Bichmann, D. Mytilineos, A. Fürstberger, H. Kestler, P.J. Schuler, T.K. Hoffmann, H.-G. Rammensee, S. Stevanovic, L. Mühlenbruch
Journal: Annals of Oncology (2019)
Abstract 15004: Real Time Lesion Assessment Using a Novel Combined Polarization-Sensitive Optical Coherence Reflectometry
Authors: Yoshinari Enomoto, Jacob S Koruth, Jorge G Panizo, Jin Iwasawa, David Herranz, Juan Sancho Dura, Jose L Rubio, Eduardo Margallo Balbas, Dinesh Sharma, Chandrasekar Palaniswamy, Anthony Gomes, Marc A Miller, Subbarao Choudry, Srinivas R Dukkipati, Vivek Y Reddy
Journal: Circulation (2016)

Introduction: Real-time lesion assessment could improve ablation efficiency and safety by allowing energy titration for transmurality. Incorporating polarization sensitive OCT (PS-OCT) within a cus...
The Croonian Lectures on a New Departure in Diabetes: Delivered before the Royal College of Physicians of London
Authors: F. W. Pavy
Journal: BMJ (1894)

61'In conclusion, I have only to emphasise that the methods which have been under discussion are not put forward as -adequately-tested therapeutic measures.They may, however, chance to be, if I may so express them unblamed, contributions to the building up of the newer and better system ef therapeutics.
Combined genomic and epigenomic assessment of cell-free circulating tumour DNA (cfDNA) for cancer diagnosis and recurrence-risk assessment in early-stage lung cancer
Authors: Junghee Lee, Il-Jin Kim, Jong Ho Cho, Hong Kwan Kim, Jinseon Lee, Se-hoon Lee, Matthew Shultz, Ariel Jaimovich, Justin Odegaard, Steve Olsen, AmirAli Talasaz, Jhingook Kim
Journal: Annals of Oncology (2019)
Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial
Authors: V. Kunzmann, H. Algül, E. Goekkurt, G.M. Siegler, U.M. Martens, D. Waldschmidt, U. Pelzer, E. Hennes, M. Fuchs, J. Siveke, F. Kullmann, S. Boeck, T.J. Ettrich, P. Ferenczy, R. Keller, C.-T. Germer, H. Stein, I. Hartlapp, I. Klein, V. Heinemann
Journal: Annals of Oncology (2019)
In situ detection of fragmented DNA (tunel assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: A cautionary note*1
Authors: B GRASLKRAUPP
Journal: Hepatology (1995)

Detection of DNA fragments in situ using the terminal deoxyribonucleotidyl transferase (TDT)-mediated dUTP-digoxigenin nick end labeling (TUNEL) assay is increasingly applied to investigate active cell death (apoptosis). We studied the specificity of the assay in well-defined models of apoptosis and necrosis as well as in postmortem autolysis in rat liver. During involution of liver hyperplasia, which follows stopping treatment with the hepatomitogens cyproterone acetate (CPA) or nafenopin (NAF), numerous apoptotic hepatocytes could be observed with TUNEL-positive chromatin residues. A similar TUNEL-positive reaction appeared in necrotic hepatocytes after a cytotoxic dose of carbon tetrachloride (CC14) or N-nitrosomorpholine (NNM). Also, in insufficiently fixed, autolytic livers TUNEL-positive nuclei were observed. Thus, DNA fragmentation is common to different kinds of cell death; its detection in situ should not be considered a specific marker of apoptosis.
INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)
Authors: M. von Mehren, C. Serrano, S. Bauer, H. Gelderblom, S. George, M. Heinrich, P. Schöffski, J. Zalcberg, P. Chi, R.L. Jones, P. Reichardt, S. Attia, G. D’Amato, J. Meade, K. Shi, R. Ruiz-Soto, J.-Y. Blay
Journal: Annals of Oncology (2019)
Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from &gt;4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study
Authors: J.S. de Bono, K. Fizazi, F. Saad, N. Shore, S.K. Sandhu, N. Mehra, M. Kolinsky, G. Roubaud, M. Özgüroǧlu, N. Matsubara, C. Gedye, Y.D. Choi, C. Padua, C. Goessl, A. Kohlmann, C. Corcoran, C.A. Adelman, A. Allen, J. Burgents, M. Hussain
Journal: Annals of Oncology (2019)
MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer
Authors: G.W. Sledge, M. Toi, P. Neven, J. Sohn, K. Inoue, X. Pivot, O. Burdaeva, M. Okera, N. Masuda, P.A. Kaufman, H. Koh, E.-M. Grischke, P.F. Conte, Y. Lu, S. Barriga, K. Hurt, M. Frenzel, S.R.D. Johnston, A. Llombart-Cussac
Journal: Annals of Oncology (2019)
Ex Vivo Expansion of Human Marrow Mesenchymal Stem Cells: A Serum-Free Medium Compared to Classical α-MEM Medium.
Authors: Nathalie Meuleman, Tatiana Tondreau, Alain Delforge, Marielle Dejeneffe, Martine Massy, Dominique Bron, Laurence Lagneaux
Journal: Blood (2004)
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
Authors: T. André, D. Vernerey, S.A. Im, G. Bodoky, R. Buzzoni, S. Reingold, F. Rivera, J. McKendrick, W. Scheithauer, G. Ravit, G. Fountzilas, W.P. Yong, R. Isaacs, P. Österlund, J.T. Liang, G.J. Creemers, M. Rakez, E. Van Cutsem, D. Cunningham, J. Tabernero, A. de Gramont
Journal: Annals of Oncology (2020)
Trends in Surgery for Children Younger Than 3 Years From 1998 to 2017
Authors: Ethan L. Sanford, Nina N. Sanford, Adam Alder, Peter Szmuk
Journal: JAMA Pediatrics (2019)

Pediatrician adherence for infants at high risk was 62.5% (n = 5 of 8) in the iREACH clinic; however, the sample size of infants at high risk in the non-iREACH clinic (n = 1) was not sufficient to detect a difference (P = .44).Among all infants at high risk, pediatricians referred to allergists (n = 3 of 9) more often than they ordered a peanut sIgE (n = 2 of 9).Additionally, 10 infants (2.2%) at low-moderate risk from both clinics were referred to an allergist or had a peanut sIgE ordered.Discussion | Higher pediatrician guideline adherence was observed among infants in the clinic that implemented iREACH.Interestingly, more infants at low-moderate risk received a sIgE order or allergist referral than infants at high risk.Limitations of this study include (1) a limited number of clinic sites and therefore a limited number of high risk infants and (2) patients were not randomized between the iREACH and comparison clinic.Since well-child visits for infants aged 4 to 6 months focus on a range of preventative and anticipatory guidance, an effective CDS tool such as iREACH may facilitate pediatrician guideline adherence.
A new population model validated pharmacokinetic similarity of HLX01 and rituximab in B-cell lymphoma
Authors: Y. Shi, Y. Dan, Y. Hong, J. Guo, S. Zhao, X. Zeng, P. Hu, W. Jiang, S. Liu, X. Zhang, A. Luk, K. Chai, E. Liu
Journal: Annals of Oncology (2019)
Impact of abstention of diagnostic biopsy in sarcoma
Authors: A. Dufresne, G. Decanter, G. Ferron, O. Marco, E. Stoeckle, P. Meeus, F. Gouin, F. Sirveaux, A. Rochwerger, S. Bonvalot, C. Honoré, P. Anract, M. Ropars, S. Carrere, A Di Marco, F. Ducimetière, A. Italiano, A Le Cesne, N. Penel, J.-Y. Blay
Journal: Annals of Oncology (2019)
Pattern of gastric cancer in young(GCY): A retrospective study from a tertiary cancer care centre in Indian subcontinent
Authors: S. Kumar, K. Gupta, T.V. Murali, K.G. Dharma, A. Anand, M. Bhandare, V. Chaudhary, S.V. Shrikhande
Journal: Annals of Oncology (2018)
Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
Authors: K. Fujiwara, P. Harter, A. Leary, D. Perol, S. Pignata, A. González-Martín, E. Petru, E. van Nieuwenhuysen, N. Colombo, J. Mäenpää, F. Selle, N. de Gregorio, D. Lorusso, E.M. Guerra Alia, C. Lefeuvre-Plesse, P. Buderath, A. Lortholary, A. Burges, E. Pujade-Lauraine, I.L. Ray-Coquard
Journal: Annals of Oncology (2019)
A Prospective, Multi-Center, Randomized Clinical Trial to Compare the Pharmacokinetic Properties of Human-Cl rhFVIII, a New Human-Cell Line Derived Recombinant Factor VIII, with Those of a Full-Length Recombinant Factor VIII Expressed in Baby Hamster Kidney Cells,
Authors: Sigurd Knaub, Andreas Tiede, Toshko Lissitchkov, Leonard A. Valentino, Jerry Sherman Powell, Marilyn J. Manco-Johnson
Journal: Blood (2011)